THE ECONOMIC IMPLICATIONS OF RASBURICASE TREATMENT IN ADULT TUMOR LYSIS SYNDROME PATIENTS

被引：0
|
作者：
Eaddy, M. [1 ]
Seal, B. [2 ]
Tangirala, M. [3 ]
O'Day, K. [1 ]
机构：
[1] Xcenda, Palm Harbor, FL USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Smith Harley Consulting Grp LLC, Lake Mary, FL USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73261-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A40 / A40
页数：1
相关论文
共 50 条
  • [31] The value of low, fixed, single dose rasburicase in the prevention and treatment of tumor lysis syndrome.
    Ponnada, Bharadwaj
    Raghuram, Saadvik
    Kotne, Sanketh
    Keechilat, Pavithran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
    Zaidi, SZA
    Aljurf, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3430 - 3431
  • [33] Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome
    Sanchez Tatay, V.
    Lopez Castilla, J. D.
    Carmona Ponce, J. M.
    Perez Hurtado, J. M.
    Quiroga Cantero, E.
    Loscertales Abril, M.
    ANALES DE PEDIATRIA, 2010, 72 (02): : 103 - 110
  • [34] Use of low dose rasburicase in the management of hyperuricemia in tumor lysis syndrome
    Jin, R.
    Shayani, S.
    Htoy, S.
    Fujinami, W.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 152 - 152
  • [35] MANAGEMENT OF TUMOR LYSIS SYNDROME WITHOUT RASBURICASE: A MODEL FOR THE DEVELOPING WORLD
    Prakash, A.
    Kowtal, P.
    Rao, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S389 - S389
  • [36] Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration
    Darmon, Michael
    Guichard, Isabelle
    Vincent, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : E67 - E68
  • [37] Single 3 mg rasburicase dose in the management of tumor lysis syndrome
    Schlei, Zachary
    Urmanski, Angela
    Falvo, Felicia
    Waggoner, Mindy
    Dow, Elizabeth
    Karpinski, Julie
    PHARMACOTHERAPY, 2014, 34 (06): : E110 - E111
  • [38] Recommendations for the management of tumor lysis syndrome (TLS) with rasburicase:: An observational survey
    Bertrand, Yves
    Mechinaud, Francoise
    Brethon, Benoit
    Mialou, Valerie
    Auvrignon, Anne
    Nelken, Brigitte
    Notz-Carrere, Anne
    Plantaz, Dominique
    Patte, Catherine
    Urbieta, Marisol
    Baruchel, Andre
    Leverger, Guy
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (04) : 267 - 271
  • [39] Role of i.v. allopurinol and rasburicase in tumor lysis syndrome
    Holdsworth, MT
    Ngltyen, P
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (21) : 2213 - 2222
  • [40] Rasburicase for Huge Hepatocellular Carcinoma with Tumor Lysis Syndrome: Case Report
    Chao, Chia-Ter
    Chiang, Chih-Kang
    MEDICAL PRINCIPLES AND PRACTICE, 2012, 21 (05) : 498 - 500
12345